Skip to main content
BioAdvance NewsENB TherapeuticsPortfolio News

ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy

By November 4, 2022November 1st, 2024No Comments

ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy

ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor – a novel immune checkpoint

See more here